Pay in 4 interest-free payments of $6.63 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Author contributions T.W.S., B.D.P., A.S, S.H.S
Researchers are now exploring GLP-1s role in a number of closely related conditions, with scientists investigating its potential benefits for metabolic health, cardiovascular health, and even broader chronic disease applications. At AgelessRx, our Stanford PhD-led Research Team is actively studying GLP-1 through a longevity lens on two fronts
Many of the cardiovascular and metabolic trials informing the discussion were not designed to evaluate ophthalmic outcomes. The authors called for prospective ophthalmology-specific studies incorporating imaging biomarkers, visual outcomes and disease-specific monitoring, noting that parsing the protective benefits or adverse effects of this rapidly growing medication class will be essential to refining disease management and improve patient outcomes. As GLP-1 therapies become increasingly common among patients with diabetes, obesity and vascular comorbiditiesprecisely the populations populating ophthalmic clinicsthe field may not have the luxury of waiting for cleaner data
If and when the oral version is approved by the US Food and Drug Administration, the lowest dose will start at $149 per month
I also rekindled my love of music by joining the Arts Chorale, a choir on campus that includes a diverse group of individuals and majors
US$ 26.78
US$ 20.62
US$ 29.88
US$ 28.14
US$ 23.31
